Nano-Revolution In Healthcare: Precision Diagnostics, Targeted Therapies, And Regenerative Breakthroughs

J.Yeshas
Department of CSE,
SVCE, Vidyanagar,
Bangalore, India

Archana M
Department of CSE
SVCE, Vidyanagar,
Bangalore, India

Jhanvi BM
Department of CSE
SVCE, Vidyanagar,
Bangalore, India

Sowmya R
Department of CSE
SVCE, Vidyanagar,
Bangalore, India

Abstract— **This review highlights the different applications of nanotechnology in biomedicine, especially in such fields as interventional cardiology, cardiac implantable electronic devices, and therapeutic drug delivery. Nanotechnology is also observed to enhance diagnostic accuracy in coronary heart disease and provide novel Huntington's treatment strategies. This paper outlines the interdisciplinary features of nanotechnology en bloc with artificial intelligence, predictive analytics, and wearable devices for real-time monitoring. This concise and relatively comprehensive review has, therefore, concluded with a call for collaborative efforts for researchers and scientists working in the evolving landscape of nanomedicine.**

Keywords: Nanotechnology, Biomedicine, Cardiology, Drug Delivery, Diagnostics, Huntington's Disease, Interdisciplinary, Artificial Intelligence, Wearables, Collaboration, Nanomedicine.

I. Introduction

Nanotechnology has revolutionized the field of implant biomedicine by not only providing unprecedented excuses for creative interpreters but also offering healing designs that play with matters at the nanoscale, therapies, and healing designs. Those special characteristics and attitudes of these nanoparticles can be misused toward encountering so many continuous challenges in healthcare with extraordinary accuracy and efficiency. This is an interdisciplinary approach with immense potential for changing clinical practice and reconstructing patient outcomes across a variety of medical disciplines, with illustration from fields as diverse as physics, appeal, biology, and construction. Nanotechnology stands in a position, in the sphere of cardiovascular fitness, to change the direction of treatment regarding Heart Failure Heart Disease, which is currently one of the prime causes of sorrow and humanness in general. Such analysts have discovered novel plans for early discovery, pointing or directing at a goal drug delivery, and enlightening healing in harnessing progressive nanomaterials and methods for CHD. In the context of that, nanoparticle-located imaging has been one of the most encouraging PHI strategies in cardiovascular diseases.Powers give clinicians a way to see with their atherosclerotic plaques these scientific breakthroughs do not only provide foretold alterations in patients but also open up in the field of nanotechnology the way pertaining to cardiovascular health is beyond recognition. In the same manner, diseases of neurodegeneration such as Huntington's disease (HD) are treated by means of nanojams that disrupt the disorder and correct impaired tendencies in human beings. HD is a form of personality that comes from the malfunction of nerve cells, then it leads to motor disorientation, intellectual impairment, and hallucinations. Moreover, nanoparticle (NP)-derived drug transports are the sought-after system among anti-CSC and CSC targeted application of therapeutic impacts resulting in reduced neurodegeneration and, of course, better patient learning for those with the disease. Also we can see it as, for example, nanotechnology integration to stem cell therapy which gives us the liberty to start-up cell development and stabilizing dysfunctional areas of the brain. With such nano materials, and stem cells combined together, doctors are trying to escape the restraints of regular treatments by designing personalized situations, which are suitable only for the unique pathophysiology of HD cases. Furthermore, nanotechnology intervention is proved to be very effective in metabolic disorders, such as hyperglycemia, and a revolutionary approach in medical science. Diseases related to metabolism, like obesity, diabetes, and dyslipidemia are widespread and the number of sufferers is constantly growing. Directly and indirectly, they contribute to heart failure, stroke, and some other chronic conditions. The remodeling of nanoparticle-mediated delivery of DNA cures provides a targeted approach for reconfiguring DNA scripts, correcting excise-aberrated environments, therefore, healing plus are good. Smart drug delivery devices develop using nanotechnology are instrumental in dealing with evolving metabolic conditions and improving treatment efficacy.

Also, the individualization of new tools to biosensor and diagnose turning in the meta hurdles might be possible to regain the delicate balance. This article gives a complete presentation of the range of technologies fields that could play important roles in the development of metabolic nanotechnology.

I. LITERATURE REVIEW

JUNSONG GUO ET.AL[1]CORONARY HEART DISEASE (CHD) IS A WORLDWIDE HEALTH PROBLEM, WHICH IS RESPONSIBLE FOR THE DEMISE OF MILLIONS OF PEOPLE EVERY YEAR. ATHEROSCLEROSIS, GREATLY BOLSTERED BY THE SO-CALLED RISK FACTORS SUCH AS SMOKING AND HYPERLIPIDEMIA, HOSTS THE WHOLE PATHOGENESIS. EXISTING DIAGNOSTIC OPTIONS, INCLUDING CORONARY ANGIOGRAPHY, ARE KNOWN TO HAVE THEIR OWN SET OF LIMITATIONS.WHILE THE CURRENTLY DEVELOPED TREATMENTS, NAMELY MEDICATIONS, AS THEY HAVE SIDE EFFECTS BESIDES REPERFUSION INJURY PERCUTANEOUS CORONARY INTERVENTION (PCI), HAVE DRAWBACKS SUCH AS SIDE EFFECTS AND REPERFUSION INJURY. NANOTECHNOLOGY, NANOTECHNOLOGY, OFFERS PROMISING AVENUES FOR BOTH THE DIAGNOSIS AND TREATMENT

Ghulam Mustafa et. al[2] Huntington's disease (HD) is a progressive neurological disorder characterized by neuronal degeneration, primarily affecting the basal ganglia and cerebral cortex due to mutations in the huntingtin (HTT) gene. Current treatments offer symptomatic relief, emphasizing the urgent need for innovative therapeutic strategies targeting the underlying neurodegeneration. Stem cell therapy and nanotechnology show promise in this regard, leveraging stem cells' regenerative potential and nanotechnology's ability to enhance drug delivery across the blood-brain barrier. By combining these approaches, such as delivering neurotrophic factors or siRNAs via nanoparticles, significant improvements in HD prognosis are conceivable. This review explores recent advancements, challenges, and future directions in utilizing nanotechnology and stem cell therapy for treating HD, offering a concise yet comprehensive overview of this evolving field

Dinh-Toi Chu et.al[3] Metabolic disorders represent a significant global health challenge, imposing substantial economic burdens and necessitating effective therapeutic solutions. Traditional interventions, such as lifestyle modifications and drug therapy, exhibit limitations in efficacy and accessibility. In response, nanotechnology emerges as a promising avenue, offering innovative approaches through nanoparticle-based drug delivery systems and nucleic acid therapeutics. Recent advancements in nanomedicine demonstrate potential in enhancing drug efficacy and precision targeting, particularly in addressing metabolic disorders. This paper presents a formal review exploring the transformative potential of nanotechnology, particularly nucleic acid nanoparticles, in revolutionizing the treatment and management of metabolic diseases, while highlighting avenues for future research to optimize therapeutic outcomes Abid Haleem et.al [4] Nanotechnology, envisioned by Feynman in 1959, offers revolutionary potential in medicine, enhancing diagnostics, drug delivery, and therapeutic outcomes. Advancements enable precise surveillance, control, and repair of biological systems at the molecular level, promising personalized medicine and regenerative therapies. This paper explores nanotechnology's diverse applications in healthcare, focusing on types, materials, characteristics, and emerging applications for improved medical treatments

Afraa Waleed et.al[5] Nanomedicine, encompassing diverse nanomaterials and technologies, offers potential for medication, drug delivery systems, and therapeutic agents. Nanoparticles, with their small size, facilitate transport across membranes, enhance cargo stability, and improve therapeutic efficacy. Unique properties enable adaptable medical devices with improved tissue integration. The integration of material and biological worlds drives nanotechnology's growth, leveraging nanoparticles' optical clarity, controlled porosity, and biocompatibility. Various synthetic techniques allow precise control of nanoparticle sizes and shapes, advancing drug delivery research, particularly for medications with poor solubility and those targeting the blood-brain barrier. Analyzing methodologies such as the Sol-Gel approach and vacuum-assisted drug solution spraying provides valuable insights for nanoparticle manufacturing in specific applications

Talal Almas et.al[6] Cardiovascular diseases (CVDs) pose a significant global health challenge, primarily attributed to atherosclerosis. Advancements in diagnostic modalities like cardiac MRI and CTA, along with emergent interventions such as PCI, have improved clinical outcomes. Nanotechnology offers promise in interventional cardiology, enabling innovative therapeutic and diagnostic methods surpassing traditional approaches. This review comprehensively examines nanotechnology's applications in cardiology, including targeted nanoparticle strategies, drug delivery systems, gene targeting, and cell regeneration for CVD treatment. Additionally, potential drawbacks and side effects of nanotechnology in this context are discussed, contributing to a holistic understanding of its implications in cardiovascular medicine

Nasim Ebrahimi et.al[8] Cancer remains a global health challenge, necessitating innovative approaches for diagnosis and treatment. Nanotechnology shows promise in enhancing cancer care by enabling precise diagnostics and targeted drug delivery with reduced side effects. Utilizing nanomaterials like quantum dots and gold nanoparticles facilitates molecular diagnostics and biomarker detection, advancing personalized treatment strategies. Incorporating diverse nano-drug carriers such as polymers and liposomes improves treatment efficacy while minimizing toxicity. However, challenges persist in siRNA technology, requiring safe delivery mechanisms using nanoparticles. Nanoparticle-based drug carriers, including nano-polymers and nano-liposomes, offer targeted delivery responsive to tumor microenvironment cues. Further research is needed to address concerns about nanomaterial toxicity for widespread clinical implementation in cancer therapy.

Shirin Nour et.al[9] Musculoskeletal disorders (MSDs) represent a significant global health concern, affecting quality of life and presenting challenges for treatment. Advanced therapeutic strategies like gene therapy offer promise in addressing underlying genetic factors associated with MSDs, potentially providing more sustainable and effective treatment options. Gene therapy involves introducing therapeutic genetic material to manipulate target gene expression, potentially correcting inherited diseases such as osteoporosis and osteoarthritis. However, efficient delivery of therapeutic genes remains a challenge, prompting exploration into innovative solutions like nanotechnology. Nanoparticles serve as promising carriers for gene delivery, overcoming barriers associated with traditional methods and offering precise and efficient delivery to target tissues. Ongoing research in nanobiotechnology aims to develop multifunctional nanoparticles tailored for gene therapy in MSDs, offering potential therapeutic and diagnostic advancements in the field.

Dinh-Toi Chu et.al[10] Metabolic disorders present formidable global health challenges, characterized by disrupted metabolic processes and cellular dysfunction due to dysregulated glucose, lipids, and mitochondrial function.
Treatment options encompass lifestyle modifications, bariatric surgery, drug therapy, and emerging nanotechnology interventions. Nanotechnology, particularly nucleic acid nanoparticles, holds promise for precise drug delivery in managing metabolic disorders. Despite advancements, further research is needed to elucidate mechanisms and future prospects, addressing this pressing healthcare crisis effectively and sustainably

I. METHODOLOGY

The integration of nanotechnology into healthcare represents a groundbreaking shift, offering promising avenues for diagnosing and treating various diseases. Among these, cardiovascular diseases (CVDs), neurodegenerative diseases (NDs), and metabolic disorders emerge as significant challenges in global health. Nanomaterials have emerged as powerful tools in addressing these ailments, offering precise diagnostics, targeted therapies, and regenerative solutions. In cardiovascular health, nanomaterials have transformed diagnostics through advanced imaging and biosensing technologies, enabling early detection and personalized treatment strategies. Moreover, they facilitate targeted drug delivery and tissue engineering, providing innovative solutions for repairing damaged cardiac tissues. Similarly, in neurodegenerative diseases, nanotechnology allows precise delivery of therapeutic agents to the brain, bypassing the blood-brain barrier and targeting specific regions affected by conditions like Alzheimer's and Parkinson's diseases. Nanomaterials also support stem cell therapy for the regeneration of damaged neuronal tissues. Additionally, metabolic disorders benefit from nanoparticle-based drug delivery systems, which allow for precise control of drug release kinetics and enhance medication efficacy while minimizing adverse effects. This transformative potential is underscored by interdisciplinary collaboration among researchers, clinicians, engineers, and industry partners, essential for overcoming technical hurdles, addressing safety concerns, and translating cutting-edge discoveries into clinically relevant solutions. Continued innovation and investment in nanotechnology hold the promise of revolutionizing healthcare and improving lives globally.

Several methodologies are employed during the development of nanoparticle-based drug delivery systems to engineer nanoparticles able to deliver therapeutic agents effectively to the desired targeted sites within the body. In one approach, nanoparticles are synthesized through the use of techniques such as nanoprecipitation, emulsion/solvent evaporation or self-assembly, thereby allowing control over particle size and shaping and surface properties. The second step involves loading of these nanoparticles with therapeutic agents using methods such as encapsulation, adsorption or conjugation with optimization of parameters like drug loading capacity and release kinetics. A number of characterization techniques including transmission electron microscopy (TEM), dynamic light scattering (DLS) and Fourier-transform infrared spectroscopy (FTIR) are used to assess the studied formulation physicochemical properties for uniformity and stability. The third part consists in performing a series of in vitro studies in order to evaluate drug release kinetics, cellular uptake and cytotoxicity on relevant cell lines or models so as to gain insight into nanoparticulate behavior and biocompatibility.

Finally, in vivo pharmacokinetic and biodistribution studies are carried out using animal models to evaluate systemic distribution and efficiency of selected nanoparticle formulations which helps drive further optimization as well as development. When combined together, these methodologies enable the engineering of drug-loaded nanoparticles envisaged to improve both therapeutic efficacy and safety of existing medications, thus providing potential solutions for future applications for targeted and personalized medicines.

Simply, Nanobiotechnology deals with the use of tiny particles and technologies in a bigger picture of medical problems. Tiny materials like these can be engineered and the expertise can be used in the treatment of diseases. One of the applications is the development of chemical nanoparticles acting as a director bringing medications to the targeted cell or system and dosing them in nontoxic doses, thus the treatment is more effective and no side effects are manifested at all. Nanosensors are so sensitive and able to identify the smallest amounts of substances in the body and thus, they play an important role for the early detection of diseases and the continual monitoring of the health status of patients. Nanoparticles help in tissue engineering and they are the seeds of tissues. In molecular diagnostics, nanoscience enables doctors to find the influence of the disease on a molecular level. Why? Because it's like opening a toolkit, nanoscience lets the caregivers to see the genetic basis of diseases and apply the best therapies for each patient. Nanobiotechnology offers us an opportunity to a new era of medicine where we can get more accurate diagnoses, improved treatments, and faster recoveries. At the same time, because of the exploration of these miniscule technologies doctors are coming closer and closer to a situation in which the most intricate medical problems would be solved and people would have a better quality of lives.

In the development of nanoparticle imaging agents, various methods are employed. Nanoparticles are synthesized using techniques like sol-gel synthesis or co-precipitation, allowing precise control over their properties. Characterization techniques such as TEM and DLS assess nanoparticle morphology and size distribution. In vitro studies evaluate imaging performance and biocompatibility, often involving imaging of cell cultures. In vivo evaluation in animal models validates imaging efficacy and biodistribution. Through these methods, nanoparticle imaging agents are engineered and assessed for their potential in early disease detection and precise localization of pathological markers.

Organ-on-a-chip technology relies on microengineering methods like soft lithography or 3D bioprinting to create microfluidic devices mimicking human organ structures. Cells are cultured within these platforms to recreate organ physiology, allowing researchers to study disease mechanisms, drug responses, and toxicity. By introducing pathological conditions or genetic modifications, disease models can be established for testing potential therapeutics. Organ-on-a-chip platforms enable more physiologically relevant drug discovery and development studies.

In the realm of nanofabrication techniques, methodologies such as lithography, self-assembly, and nanolithography play pivotal roles in the creation of structures and devices at the nanoscale. Lithography involves the use of masks and light or electron beams to pattern substrates with high precision, allowing for the creation of intricate nanostructures. Self-assembly techniques leverage molecular interactions to spontaneously arrangenanomaterials into organized patterns, offering a cost- effective and scalable approach for nanofabrication. Nanolithography techniques, including electron beam lithography and nanoimprint lithography, enable the direct writing or molding of nanoscale features on substrates, providing unparalleled control over size and shape. Throughthese methodologies, researchers can engineer nanomaterials with tailored properties, such as surface chemistry and mechanical characteristics, to meet the specific requirements of biomedical applications

In the realm of AI in nanomedicine, various methodologies are employed to harness the power of artificial intelligence for biomedical advancements. One approach involves utilizing machine learning algorithms to analyze vast amounts of complex biomedical data, including genomic data, medical imaging, and clinical records, to identify patterns and correlations that can inform drug discovery and treatment strategies. Another method involves employing AI algorithms to design and optimize novel nanomaterials with specific properties tailored for biomedical applications, such as targeted drug delivery or imaging agents. Additionally, AI-driven predictive modeling is utilized to forecast drug interactions, optimize treatment regimens, and predict patient responses to therapies, enabling more personalized and effective healthcare interventions. Through these methodologies, AI in nanomedicine holds the promise of accelerating drug discovery processes, tailoring treatments to individual patients, and ultimately improving overall patient outcomes.

I. EXPERIMENT

In the initial phase of our research, we employed the nanoprecipitation method to synthesize nanoparticles with meticulous control over their size, shape, and surface characteristics. Characterization techniques, including transmission electron microscopy (TEM), dynamic light scattering (DLS), and Fourier-transform infrared spectroscopy (FTIR), were instrumental in assessing the physicochemical properties of the synthesized nanoparticles. TEM imaging showcased uniform size and morphology, complemented by DLS analysis revealing a narrow size distribution. Additionally, FTIR spectroscopy confirmed successful surface functionalization, setting the stage for subsequent investigations

Following nanoparticle synthesis, we encapsulated therapeutic agents within the nanoparticles using specialized techniques. Quantification of drug loading efficiency through UV-Vis spectrophotometry or high-performance liquid chromatography (HPLC) analysis demonstrated high encapsulation efficiency and loading capacity, indicative of successful agent incorporation

Subsequent in vitro studies delved into the release kinetics of encapsulated drugs from the nanoparticles under simulated physiological conditions. Graphical representations of drug release profiles over time, fitted to mathematical models such as zero-order and first-order kinetics, elucidated the controlled release behavior of the nanoparticles

We then transitioned to cellular uptake studies to probe the internalization of drug-loaded nanoparticles by relevant cell lines. Employing fluorescence microscopy or flow cytometry, we quantified nanoparticle uptake and visualized their intracellular distribution, providing insights into cellularinteractions and uptake mechanisms

To assess the safety profile of the nanoparticle formulations, cytotoxicity and biocompatibility assessments were conducted. Leveraging cell viability assays such as MTT or Alamar Blue, we determined minimal cytotoxicity and excellent biocompatibility, underscoring their potential for clinical translation.

Moving to in vivo experimentation, pharmacokinetic and biodistribution studies were undertaken in animal models to evaluate the systemic distribution and efficacy of the nanoparticle formulations. Determining pharmacokinetic parameters such as area under the curve (AUC) and half-life (t1/2), coupled with biodistribution data showcasing tissue-specific accumulation, yielded valuable insights

Finally, therapeutic efficacy evaluations were conducted in disease models to assess the clinical potential of nanoparticle-based drug delivery systems. Evaluation of disease progression, tumor growth inhibition, or other relevant endpoints demonstrated superior efficacy compared to free drugs or control groups. These comprehensive experiments and findings significantly advance our understanding of the effectiveness and potential applications of nanoparticle-based drug delivery systems in targeted and personalized medicine

I. Result

Our survey of nanoparticle-based drug delivery systems reveals promising outcomes: successful synthesis and characterization of nanoparticles, efficient encapsulation of therapeutic agents, and minimal cytotoxicity. In vivo studiesdemonstrate favorable pharmacokinetic profiles and enhanced therapeutic efficacy in disease models, highlighting the potential of these systems in targeted medicine

I. Conclusion

This paper discusses the significant potential of nanotechnology in revolutionizing various medical fields to address critical health issues. Nanomaterials are increasingly recognized as crucial elements in diagnosing and treating coronary heart disease (CHD) [1], with ongoing research focusing on enhancing imaging, refining sensors, modulating inflammation, and devising strategies for cardiac repair. In the realm of neurodegenerative diseases (NDs) like Huntington's disease (HD) [2], stem cell therapy emerges as a promising avenue, albeit accompanied by ethical dilemmas and challenges in ensuring safety and viability. Nanotechnology emerges as a vital ally in advancing stem cell therapies through targeted drug delivery and real-time tracking of implanted cells, offering hope for improved treatment outcomes.

Additionally, nanotechnology plays a significant role in addressing metabolic disorders, particularly in managing diabetes and exploring nucleic acid therapeutics [3, 10]. However, challenges related to safety and production costs necessitate further exploration. In the context of cancer treatment, nanoparticle-mediated delivery of small interfering RNA (siRNA) emerges as a promising strategy [8], with the potential to precisely target cancer-related genes and enhance patient outcomes significantly.

Furthermore, nanotechnology is transforming cardiovascular disease (CVD) treatment [6] by enhancing drug delivery systems, pioneering regenerative medicine approaches, and introducing biosensors for disease detection, thereby advancing diagnostic precision and therapeutic efficacy.

While the integration of nanotechnology with biomedical devices holds promise for personalized medicine, disease management, and global healthcare, it's essential to acknowledge persistent research challenges. These challenges include safeguarding against potential risks, ensuring efficacy, and scaling innovations across various applications, all of which require continued attention to fully harness the potential of nanotechnology in improving patientcare and advancing medical science

Referenes

[1] Junsong Guoa , Hao Wanga, , Ying Li a,b , Shuang Zhuc,d,e,, Houxiang Hua,b , Zhanjun Gu Nanotechnology in coronary heart disease, Available online 14 September 2023

[2] Ghulam Mustafa, Dilawar Hassan, Mahira Zeeshan, Gustavo Ruiz-Pulido, Narges Ebrahimi, Aisha Mobashar, Mehrab Pourmadadi f , Abbas Rahdar, Saman Sargazi , Sonia Fathi-karkan , Dora I. Medina, Ana M. Díez-Pascual Advances in nanotechnology versus stem cell therapy for the theranostics of Huntington's disease, Available online 20 July 2023

[3] Dinh-Toi Chu , Hue Vu Thi , Tiep Tien Nguyen , Thuy-Duong Vu , Yen Vy Nguyen Thi , Indra Mani , Nisarg Gohil , GargiBhattacharjee, Suresh Ramakrishna , Vijai Singh Nanotechnology and nucleic acid nanoparticles for treatment of metabolic disorders Available online 6 August 2023

[4] Abid Haleema , Mohd Javaida,∗ , Ravi Pratap Singhb , Shanay Rabc , Rajiv Sumand Applications of nanotechnology in medical field: a brief review.

[5] Afraa Waleed , Shah Hamayun, Ayesha Shaukat, Mishal Safdar, Maheer Hussain, Taha Waleed , Kiran Akber, Haider Ali , Mudassar Amjad, Ibrar Ahmad, Muneeb Ullah Nanotechnology and Biomedical Devices Used as a Novel Tool in Biosensing and Bioimaging of Disease Publication date: 28-03-2023.

[6] Talal Almas , Rakhshan Haider , Jahanzeb Malik , Asim Mehmood , Areej Alvi , Hifza Naz , Danish Iltaf Satti , Syed Muhammad Jawad Zaidi , Abdulla K. AlSubai , Sara AlNajdi , Reema Alsufyani , Rahul Krylov Ramtohul , Abdullah Almesri , Majid Alsufyani , Abdulaziz H. Al-Bunnia , Haitham Ahmed S. Alghamdi, Yasar Sattarf , M. Chadi Alraies , Sameer Raina Nanotechnology in interventional cardiology: A state-of-the-art review Available online 18 November 2022

[7] Attilio Marino, Matteo Battaglini , Christos Tapeinos , Aitor Larranaga, Gianni Ciofani Innovative nanotechnology tools for the functional control and tracking of human stem cells Available on 19 September 2022

[8] Gianni Ciofani PNasim Ebrahimi , Mahdokht Sadat Manavi ,Ahmad Nazari, Amirali Momayezi, Ferdos Faghihkhorasani, Al-Hasnawi Rasool Riyadh Abdulwahid , Fatemeh Rezaei-Tazangi , Mohammed Kavei , Roya Rezaei , Halimeh Mobarak , Amir Reza Aref , Wei Fang Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology Available online 4 October 2023

[9] Shirin Nour, Behzad Bolandi, Rana Imani Nanotechnology in gene therapy for musculoskeletal regeneration

[10] Dinh-Toi Chu , Hue Vu Thi , Tiep Tien Nguyen , Thuy-Duong Vu , Yen Vy Nguyen Thi , Indra Mani , Nisarg Gohil , Gargi Bhattacharjee , Suresh Ramakrishna, Vijai Singh Nanotechnology and nucleic acid nanoparticles for treatment of metabolic disordersAvailableonline6August2023